The emergence of fungi as major hospital pathogens

Journal of Hospital Infection

Volumn 11, Issue SUPPL. A, 1988, Pages 411-426

  Bodey, Gerald P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CILOFUNGIN; CLOTRIMAZOLE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE;

BONE MARROW SUPPRESSION; CLINICAL FEATURE; FUNGUS; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; LABORATORY DIAGNOSIS; MYCOSIS; NEPHROTOXICITY; PROPHYLAXIS; RISK FACTOR; SYSTEMIC MYCOSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CROSS INFECTION; FUNGI; HUMAN; IMMUNOLOGIC DEFICIENCY SYNDROMES; MYCOSES; RISK FACTORS; VIRULENCE;

EID: 0023921730     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/0195-6701(88)90220-4     Document Type: Article

References (41)

1. Ketoconazole prophylaxis of fungal infections in the granulocytopenic patient: A double-blind, randomized controlled trial
2. Invasive aspergillosis in acute leukaemia: Correlation with nose cultures and antibiotic use
3. Correlation between infection and status of underlying disease: a new look at infection in acute leukaemia (Abstract)
4. Leukopenia and therapy in leukemia as factors predisposing to fatal mycoses
5. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis
6. Fungal infections complicating acute leukemia
7. Fever and infection in leukemic patients. A study of 494 consecutive patients
8. Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study
9. Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment
10. Outbreak of systemic Candida albicans in intensive care unit caused by cross infection
11. Distribution and activity of amphotericin B in humans
12. Incidence of polyene-resistant yeasts recovered from clinical specimens
13. Early infections in kidney, heart and liver transplant recipients on cyclosporine
14. Infection prophylaxis of acute leukemia: Comparative effectiveness of trimethoprimsulfamethoxazole, ketoconazole, and trimethoprimsulfamethoxazole + ketoconazole
15. Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients
16. In vitro and in vivo antiCandida activity and toxicology of LY 121019
17. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy
18. Acute disseminated (septicaemic) moniliasis in adults and children
19. Miconazole therapy for treatment of fungal infections in cancer patients
20. Host factors in defense against fungal infections
21. Concept of empiric therapy with antibiotic combinations. Indications and limits
22. Cryptococcosis in the acquired immunodeficiency syndrome
23. Laboratory diagnosis of candidiasis
24. Leukocyte candidacidal activity and resistance to systemic candidiasis in patients with cancer
25. Aspergillosis and mucormycosis: two types of opportunistic fungal pneumonia
26. Treatment of disseminated candidiasis in neutropenic mice with liposome-encapsulated amphotericin B
27. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study
28. Disseminated moniliasis in the adult
29. Systemic Candidiasis in cancer patients
30. Fungemia in the immunocompromized host
31. Infection in bone marrow transplantation
32. Prophylaxis of oral candidiasis with clotrimazole troches
33. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
34. Monilia sepsis in the surgical patient
35. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes
36. Prophylactic ketoconazole for the prevention of fungal infection in bone marrow transplant patients
37. Candida sepsis. Pathogenesis and principles of treatment
38. Candida tropicalis: a major pathogen in immunocompromised patients
39. Aspergillosis. The spectrum of the disease in 98 patients
40. Fungemia with compromised host resistance. A study of 70 cases
41. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis